EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Engineering combination nanomedicines to overcome cancer resistance

Hina Singh, Sri Renukadevi Balusamy, Johan Sukweenadhi, Anupama Shrivastav, Aruchamy Mohanprasanth iD, Muthupandian Saravanan iD, Ivan Mijakovic, Priyanka Singh iD

RSC Advances · 2026 · 16 (6) · 5128-5167

DOI: 10.1039/d5ra08728g ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Hina Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Sciences, School of Medicine, University of California Riverside CA 92521 USA Hina.Singh@medsch.ucr.edu. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Lundbeck Foundation, Indian Council of Medical Research, Novo Nordisk Fonden.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review examines engineered combination nanomedicine strategies that integrate co-delivery platforms, tumor microenvironment targeting, and predictive translational models to overcome cancer drug resistance.

Autor:innen und Institutionen

  • Division of Biomedical Sciences, School of Medicine, University of California Riverside CA 92521 USA Hina.Singh@medsch.ucr.edu.
  • Department of Food Science and Biotechnology, Sejong University Gwangjin Gu Seoul 05006 Republic of Korea.
  • Faculty of Biotechnology, University of Surabaya Raya Kalirungkut, Kalirungkut Surabaya 60293 Indonesia.
  • Center of Excellence for Food Products and Health Supplements for Degenerative Conditions, University of Surabaya Surabaya 60293 Indonesia.
  • Faculty of Life, Health and Allied Sciences, Institute of Technology and Management, ITM Vocational University Vadodara 391760 India.
  • Applied Nano-Bio Therapeutics Laboratory, Department of Periodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences Chennai 600 077 India.

ORCID-Profile: Aruchamy Mohanprasanth, Muthupandian Saravanan, Priyanka Singh

Förderung

  • Lundbeck Foundation
  • Indian Council of Medical Research
  • Novo Nordisk Fonden
  • Danmarks Frie Forskningsfond

Zitieren

APA

Singh, H., Balusamy, S. R., Sukweenadhi, J., Shrivastav, A., Mohanprasanth, A., Saravanan, M., Mijakovic, I., & Singh, P. (2026). Engineering combination nanomedicines to overcome cancer resistance. RSC Advances, 16(6), 5128-5167. https://doi.org/10.1039/d5ra08728g

Vancouver

Singh H, Balusamy SR, Sukweenadhi J, Shrivastav A, Mohanprasanth A, Saravanan M, et al. Engineering combination nanomedicines to overcome cancer resistance. RSC Advances. 2026;16(6):5128-5167. doi:10.1039/d5ra08728g

BibTeX
@article{Singh2026,
  author = {Singh, Hina and Balusamy, Sri Renukadevi and Sukweenadhi, Johan and Shrivastav, Anupama and Mohanprasanth, Aruchamy and Saravanan, Muthupandian and Mijakovic, Ivan and Singh, Priyanka},
  title = {Engineering combination nanomedicines to overcome cancer resistance},
  journal = {RSC Advances},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {5128--5167},
  doi = {10.1039/d5ra08728g}
}
Kostenlos starten →